- Home
- TDUP vs BBNX Comparison
TDUP vs BBNX Comparison
Compare TDUP & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | BBNX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 750.9M | 613.7M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TDUP | BBNX |
|---|---|---|
| Price | $4.52 | $13.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $12.50 | ★ $27.58 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 03-02-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $298,376,000.00 | $88,570,000.00 |
| Revenue This Year | $20.94 | $53.88 |
| Revenue Next Year | $11.73 | $34.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 41.65 | ★ 67.01 |
| 52 Week Low | $2.02 | $8.89 |
| 52 Week High | $12.28 | $32.71 |
Technical Indicators
Market Signals| Indicator | TDUP | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 33.41 |
| Support Level | $4.46 | $13.25 |
| Resistance Level | $4.83 | $15.53 |
| Average True Range (ATR) | 0.31 | 0.99 |
| MACD | 0.02 | 0.47 |
| Stochastic Oscillator | 11.65 | 42.55 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.